[ad_1]
SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Corporation (“ZYUS” or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced its 2023 Third Quarter Business results. During the third quarter of 2023, the Company completed an evaluation of the transactions relating to the Arrangement Agreement with Phoenix and the accounting treatment of tho
[ad_2]
Source link
